A 63-Year-Old Man Presents With Cough & Shortness of Breath

Phase 1/2 SYLT-023 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in patients with advanced, HER2-negative, mismatch repair–proficient gastric/GEJ cancer.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Adding trastuzumab and pertuzumab to chemotherapy conferred higher toxicity among patients with HER2-positive gastric cancers in the INNOVATION trial.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

The CheckMate 649 trial found that nivolumab plus chemotherapy lead to a median OS of 14.3 months vs 10.3 months for chemotherapy alone in several gastrointestinal cancers.

Select patients may be eligible to continue treatment with tabelecleucel or ATA3219 in accordance with study protocols.